Table 1 Clinical data and outcome of all patients according to CD56 expression
From: Evaluating the prognostic value of CD56 in pediatric acute myeloid leukemia
Patients data | CD56(+) (n = 62) | CD56(−) (n = 83) | p |
|---|---|---|---|
Age(Months) | |||
Median(range) | 64(10–176) | 86(8–168) | 0.110 |
≤ 3 years(n,%) | 22(35.5%) | 18(21.7%) | 0.066 |
> 3 years(n,%) | 40(64.5%) | 65(78.3%) | |
Sex(n,%) | |||
Male | 31(50.0%) | 52(62.7%) | 0.128 |
Female | 31(50.0%) | 31(37.3%) | |
WBC at diagnosis (n,%) | |||
< 50 × 109/L | 44(71.0%) | 54(65.1%) | 0.452 |
≥ 50 × 109/L | 18(29.0%) | 29(34.9%) | |
Extramedullary infiltration(n,%) | |||
Yes | 6(9.7%) | 7(8.4%) | 0.795 |
No | 56(90.3%) | 76(91.6%) | |
Risk stratification (n,%) | |||
Standard risk | 8(12.9%) | 18(21.7%) | 0.391 |
Intermediate risk | 41(66.1%) | 50(60.2%) | |
High risk | 13(21.0%) | 15(18.1%) | |
FAB classification (n,%) | |||
M0 | 3(4.8%) | 1(1.2%) | 0.413 |
M1 | 2(3.2%) | 0(0.0%) | |
M2 | 19(30.6%) | 23(27.7%) | |
M4 | 2(3.2%) | 3(3.6%) | |
M5 | 24(38.7%) | 43(51.8%) | |
M6 | 1(1.6%) | 2(2.4%) | |
M7 | 3(4.8%) | 3(3.6%) | |
Unclassified | 8(12.9%) | 8(9.6%) | |
Clinical outcome (n,%) | |||
CR1a | 51(82.3%) | 75(90.4%) | 0.153 |
CR2b | 54(87.1%) | 80(96.4%) | 0.076 |
Resistant | 8(12.9%) | 3(3.6%) | 0.076 |
Relapse | 7(11.3%) | 5(6.0%) | 0.255 |
Death | 13(21.0%) | 11(13.3%) | 0.216 |